What is Rifaximin 400 used for?
In the pharmaceutical industry, Rifaximin 400 mg is a unique, non-systemic antibiotic belonging to the rifamycin class. As a pharmacist and manufacturer, I view Rifaximin as a “gut-targeted” therapy. Unlike standard antibiotics that circulate through the entire bloodstream, Rifaximin remains almost entirely in the gastrointestinal tract, providing localized action with minimal systemic side effects.
Primary Clinical Uses
Hepatic Encephalopathy (HE): Specifically used to reduce the risk of recurrence of overt HE in adults with chronic liver disease. It helps lower the ammonia-producing bacteria in the gut.
Irritable Bowel Syndrome with Diarrhea (IBS-D): Indicated for adults to manage the symptoms of bloating, abdominal pain, and loose stools by modulating the gut microbiota.
Traveler’s Diarrhea: Used to treat diarrhea caused by non-invasive strains of Escherichia coli in patients 12 years of age and older.
Small Intestinal Bacterial Overgrowth (SIBO): Frequently used off-label by gastroenterologists to treat an overgrowth of bacteria in the small intestine.
Mechanism of Action: RNA Synthesis Inhibition
Rifaximin works by stopping the bacteria from reproducing without killing the beneficial bacteria in the same way systemic antibiotics might.
Enzyme Targeting: It binds to the beta-subunit of bacterial DNA-dependent RNA polymerase.
Transcription Blockade: This binding inhibits the transcription of DNA into RNA, preventing the bacteria from synthesizing essential proteins.
Bacteriostatic Action: It primarily stops the growth of both Gram-positive and Gram-negative aerobic and anaerobic bacteria in the gut.
Non-Absorbability: Due to its chemical structure, less than 0.4% of the drug is absorbed into the blood. This ensures high concentrations in the feces and near-zero impact on other organs like the kidneys or lungs.
The Manufacturer’s Perspective: Technical & Export
From a production and B2B standpoint at your WHO-GMP facility in Mumbai, the 400 mg strength is a high-value specialty item:
The 400 mg “Sweet Spot”: While 200 mg is used for Traveler’s Diarrhea and 550 mg is the standard for Hepatic Encephalopathy, the 400 mg dose is a highly versatile intermediate often used in customized IBS-D protocols. Offering this strength on your digital platform sets you apart from firms only carrying the standard 200/550 mg.
Polymorphism Control: Rifaximin exists in several polymorphic forms (, , , , and ). As a manufacturer, you know that the (Alpha) form is preferred for its low absorption. Ensuring your Certificate of Analysis (COA) specifies the polymorph type is a major USP for international B2B buyers.
Stability & Bioavailability: Although it is non-systemic, the dissolution profile must be strictly controlled to ensure the drug is released at the correct site in the intestine. We utilize Alu-Alu blister packaging to protect the API from the high humidity of Zone IVb regions.
Dossier Support: This is a “Specialty Product” with high margins. Our Mumbai facility provides full CTD/eCTD Dossiers to support your export registrations against the innovator (Xifaxan).